Semaglutide
Also known as Ozempic · Wegovy
A long-acting GLP-1 receptor agonist used for type-2 diabetes and chronic weight management — the active ingredient in Ozempic and Wegovy.
Definition
A 31-amino-acid GLP-1 analog engineered with fatty-acid modifications to extend its half-life to roughly seven days, allowing once-weekly dosing. Clinical trials (STEP-1, STEP-3, SELECT) documented weight reduction of 10-15% at 68 weeks alongside cardiovascular risk improvements. Meto dispenses compounded versions from 503A pharmacies to members lacking brand-name insurance coverage.
How Meto uses it.
Prescribed as compounded semaglutide at 2.5 mg/mL concentration in multi-dose vials. Dosing begins at 0.25 mg weekly, titrated toward 1.7-2.4 mg target over 16-20 weeks via weekly subcutaneous injection with insulin syringe, rotating sites. BPC-157 may be added for members experiencing titration-delaying nausea.
Safety notes
- Contraindicated with personal/family medullary thyroid cancer or MEN 2 history
- Contraindicated in active pancreatitis
- Not recommended during pregnancy (>=2 month washout before conception advised)
- Requires pairing with resistance training and >=1.2 g/kg daily protein for lean mass preservation
- Discontinue before elective anesthesia per current GI-aspiration protocols
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
How does it compare to Tirzepatide?
Tirzepatide produces more weight loss in head-to-head trial data — 20% at 72 weeks versus semaglutide's 15%, though semaglutide maintains longer safety history.
Compounded vs. branded?
The active ingredient is identical; formulation base and pharmacy differ, with third-party testing for all batches.
What happens upon discontinuation?
Partial weight regain is common without lifestyle change — roughly two-thirds of the lost weight returns within a year.
Read More
GLP-1 Receptor AgonistGLP-1 RA
A peptide drug class that mimics glucagon-like peptide-1 to slow gastric emptying, sharpen insulin response and quiet food-noise.
PeptideTirzepatideMounjaro
A dual GLP-1 and GIP receptor agonist — the most effective FDA-approved weight-management peptide to date, the active ingredient in Mounjaro and Zepbound.
Pharmacy & RegulationCompounded Peptide
A peptide prepared for an individual patient by a licensed compounding pharmacy, prescribed by a clinician and tested for identity, potency and contamination.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.